公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study | Suzuki K.; Dimopoulos M.A.; Takezako N.; Okamoto S.; Shinagawa A.; Matsumoto M.; Kosugi H.; Yoon S.-S.; SHANG-YI HUANG ; Qin X.; Qi M.; Iida S. | Blood Cancer Journal | 21 | 23 | |
2019 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network | Soekojo C.Y.; Kim K.; SHANG-YI HUANG ; Chim C.-S.; Takezako N.; Asaoku H.; Kimura H.; Kosugi H.; Sakamoto J.; Gopalakrishnan S.K.; Nagarajan C.; Wei Y.; Moorakonda R.; Lee S.L.; Lee J.J.; Yoon S.-S.; Kim J.S.; Min C.K.; Lee J.-H.; Durie B.; Chng W.J. | Blood Cancer Journal | 12 | 7 |